Free Equity Delivery
Flat ₹10 per Trade in Intraday & F&O
| Review By | Apply | May Apply | Neutral | Avoid | Not Rated |
|---|---|---|---|---|---|
| Count | 0 | 0 | 0 | 0 | 0 |
| % | 0 | 0 | 0 | 0 | 0 |
[Dilip Davda] IHL operates as CDMO for healthcare products with its three units. It marked steady progress in its top lines for the reported periods. The sudden boost in its bottom lines for FY24 and FY25 raise eyebrows and concern over its sustainability going forward as it is operating in a highly competitive and fragmented segment. Based on its recent financial data, the issue appears fully priced. Well-informed/cash surplus investors may park moderate funds for medium term. Read detail review...
Influx Healthtech Limited peer comparison with similar listed entities. (As on March 31, 2025)
| Company Name | EPS (Basic) | EPS (Diluted) | NAV (per share) (Rs) | P/E (x) | RoNW (%) | P/BV Ratio | Financial statements |
|---|---|---|---|---|---|---|---|
| Sudarshan Pharma Industries Ltd | 0.66 | 0.66 | 5.30 | 48.28 | 12.45 | 6.20 | Consolidated |
| Quest Laboratories Limited | 8.28 | 8.28 | 49.92 | 10.38 | 16.58 | 1.73 | Consolidated |
| Influx Healthtech | 7.36 | 7.36 | 19.91 | 36.98 | Consolidated |
Notes:
Influx Healthtech IPO Reviews, analysis and views by popular members. Read Influx Healthtech Ltd. IPO reviews by retail investors to find recommended ipo to buy.
| Review By | Apply | May Apply | Neutral | Avoid |
|---|---|---|---|---|
| Count | 0 | 0 | 0 | 0 |
| % | 0.00 | 0.00 | 0.00 | 0.00 |
| Member | Review |
|---|---|
| No recommendation found. Be the first to post the recommendation. | |
Note:
RHP